Higher expression of ZEB1 associated with higher aggressive capacity, poor differentiation, development of metastases, and poor clinical prognosis had recently been revealed in endometrial cancers, colorectal carcinomas, and prostate cancer [15, 28, 29]. Here, ZEB1 is linked to endometrial cancer.